Fortress Biotech Inc FBIO:NASDAQ

Last Price$1.21Cboe Closing Price as of 3:59PM ET 8/10/22
Cboe Real-Time Quotes
Today's Change+0.10(9.01%)
Bid (Size)$0.93 (100)
Ask (Size)$1.42 (100)
Day Low / High$1.13 - 1.22
Volume178.0 K

Fortress Biotech Unit Doses First Patient in Early-Stage Gout Trial in US

11:06AM ET 5/31/2022 MT Newswires
Fortress Biotech (FBIO) said Tuesday its UR-1 Therapeutics unit has dosed the first patient in a phase 1 trial of Dotinurad for the treatment of gout in the US.

The placebo-controlled study has been designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of Dotinurad in Western subjects, Fortress Biotech said.

In May 2021, Fortress struck a licensing deal with Fuji Yakuhin to develop Dotinurad in North America and Europe. Dotinurad was approved in Japan in 2020 as once-daily oral therapy for gout and hyperuricemia.

Price: 0.91, Change: +0.01, Percent Change: +1.07